US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Arvinas, Inc. - Common Stock (NQ:ARVN)

7.900 +0.300 (+3.95%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
7 Analysts Have This to Say About Arvinas ↗
 
Via Benzinga
News headline image
Barclays Maintains Overweight Rating for Arvinas: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP) 
From Arvinas Inc.
Via GlobeNewswire
News headline image
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Collaboration expands Carrick’s clinical-stage Oncology program 
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
What 8 Analyst Ratings Have To Say About Arvinas ↗
 
Via Benzinga
News headline image
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
News headline image
6 Analysts Have This to Say About Arvinas ↗
 
Via Benzinga
News headline image
Looking Into Arvinas's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Where Arvinas Stands With Analysts ↗
 
Via Benzinga
News headline image
Arvinas: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Arvinas Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
6 Analysts Have This to Say About Arvinas ↗
 
Via Benzinga
News headline image
Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations ↗
Arvinas Inc (NASDAQ: ARVN) announced interim data from its Phase 1/2 dose escalation and expansion trial of ARV-766 in metastatic  
Via Benzinga
News headline image
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Where Arvinas Stands With Analysts ↗
 
Via Benzinga
Where Arvinas Stands With Analysts ↗
 
Via Benzinga
News headline image
Warner Bros. Discovery To Rally Around 62%? Here Are 10 Other Analyst Forecasts For Monday ↗
Wells Fargo raised the price target for Stanley Black & Decker, Inc. (NYSE: SWK) from $85 to $90. Wells Fargo analyst Joe O'Dea maintained an Equal-Weight rating. Stanley Black & Decker shares rose 3%... 
Via Benzinga
News headline image
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present at Stifel Targeted Oncology Day
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. 
Via MarketBeat
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >